IP Library › Granted Patent US 12,264,203
Granted Patent B2
US 12,264,203 · App. 18/731,146 · Granted Apr 1, 2025

Humanized complement 5a receptor 1 antibodies and methods of use thereof

Inventors: Karthik Viswanathan (Waltham, MA); Brian Booth (Waltham, MA); Boopathy Ramakrishnan (Waltham, MA); Andrew Wollacott (Waltham, MA); Gregory Babcock (Waltham, MA); Zachary Shriver (Waltham, MA); Lauren Olinski (Waltham, MA)
Assignee: Visterra, Inc.
C07K16/2896A61P37/02A61K2039/505C07K2317/24C07K2317/33C07K2317/52C07K2317/565C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,203
App. No.
18/731,146
Granted
Apr 1, 2025
Kind
B2
Abstract

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Claims (15)

1. An antibody or antigen binding fragment thereof that binds complement component 5a receptor 1 (C5aR1), comprising a heavy chain variable (VH) region, wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2, and HCDR3 sequences comprising amino acid sequences of SEQ ID Nos: 6, 7, and 8, respectively and a light chain variable (VL) region, wherein the VL comprises three light chain complementarity determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 sequences of SEQ ID Nos: 9, 10, and 11, respectively.

2. The antibody or antigen binding fragment thereof of claim 1 , wherein the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 14.

3. The antibody or antigen binding fragment thereof of claim 2 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14.

4. The antibody or antigen binding fragment thereof of claim 1 , wherein the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 25.

5. The antibody or antigen binding fragment thereof of claim 4 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 25.

6. An antibody or antigen binding fragment thereof, that binds complement component 5a receptor 1 (C5aR1) comprising:

a heavy chain variable region (VH) of SEQ ID NO: 14; and

a light chain variable region (VL) of SEQ ID NO: 25.

7. The antibody or antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody or antigen binding fragment thereof, further comprises a Fc region.

8. The antibody or antibody or antigen binding fragment thereof according to claim 7 , wherein the Fc domain is independently selected from IgG1, IgG2, IgG3, and IgG4.

9. The antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment is humanized.

10. The antibody or the antigen binding fragment thereof of claim 1 , wherein the VH or the VL has been modified to enhance the stability of the molecule.

11. A nucleic acid encoding the antibody or antigen binding fragment of claim 1 .

12. A cell comprising the nucleic acid of claim 11 .

13. A composition comprising the antibody or antigen binding fragment of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2025
From: VISWANATHAN, KARTHIK; BOOTH, BRIAN; RAMAKRISHNAN, BOOPATHY; WOLLACOTT, ANDREW; BABCOCK, GREGORY; SHRIVER, ZACHARY; OLINSKI, LAUREN
To: VISTERRA, INC.
Reel/Frame 069892/0233 →
Continuity (5)
Division 18415419 · Jan 17, 2024
Division 17575420 · Jan 13, 2022
Provisional Application 63274748 · Nov 2, 2021
Provisional Application 63137089 · Jan 13, 2021
Related Publication 20240392029A1 · Nov 28, 2024
References Cited (146)
US 5480974A · Morgan et al. · 1996 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7455837B2 · Guo et al. · 2008 [cited by applicant]
US 7632497B2 · Stavenhagen · 2009 [cited by applicant]
US 7863419B2 · Taylor et al. · 2011 [cited by applicant]
US 8071096B2 · Mackay · 2011 [cited by applicant]
US 8071839B2 · Mackay · 2011 [cited by applicant]
US 8084024B2 · Mackay · 2011 [cited by applicant]
US 8084582B2 · Dahiyat et al. · 2011 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8124731B2 · Lazar et al. · 2012 [cited by applicant]
US 8221757B2 · Mackay · 2012 [cited by applicant]
US 8268972B2 · Whitfeld et al. · 2012 [cited by applicant]
US 8318917B2 · Taylor et al. · 2012 [cited by applicant]
US 8337852B2 · Mackay · 2012 [cited by applicant]
US 8361468B2 · Whitfeld et al. · 2013 [cited by applicant]
US 8399618B2 · Lazar et al. · 2013 [cited by applicant]
US 8563259B2 · Lambris et al. · 2013 [cited by applicant]
US 8613926B2 · Kjaergaard et al. · 2013 [cited by applicant]
US 8673305B2 · Mackay · 2014 [cited by applicant]
US 8734791B2 · Lazar et al. · 2014 [cited by applicant]
US 8808701B2 · Whitfeld et al. · 2014 [cited by applicant]
US 8815237B2 · Wittrup et al. · 2014 [cited by applicant]
US 8846045B2 · Kjaergaard et al. · 2014 [cited by applicant]
US 8940299B2 · Medof et al. · 2015 [cited by applicant]
US 8952132B2 · Georgiou et al. · 2015 [cited by applicant]
US 8961967B2 · Strohl et al. · 2015 [cited by applicant]
US 8969526B2 · Baehner et al. · 2015 [cited by applicant]
US 9073983B2 · Guo et al. · 2015 [cited by applicant]
US 9180205B2 · Zeng et al. · 2015 [cited by applicant]
US 9458233B2 · Guo et al. · 2016 [cited by applicant]
US 9637549B2 · Strohl et al. · 2017 [cited by applicant]
US 9658236B2 · Mcknight et al. · 2017 [cited by applicant]
US 9683050B2 · Zeng et al. · 2017 [cited by applicant]
US 9790268B2 · Pan et al. · 2017 [cited by applicant]
US 9890218B2 · Mimoto et al. · 2018 [cited by applicant]
US 10053513B2 · Mccarthy et al. · 2018 [cited by applicant]
US 10183999B2 · Lazar et al. · 2019 [cited by applicant]
US 10323097B2 · Kjaergaard et al. · 2019 [cited by applicant]
US 10526408B2 · Georgiou et al. · 2020 [cited by applicant]
US 10590206B2 · Labrijn et al. · 2020 [cited by applicant]
US 10653791B2 · Lonberg et al. · 2020 [cited by applicant]
US 10774136B2 · Gou et al. · 2020 [cited by applicant]
US 10836813B2 · Pan et al. · 2020 [cited by applicant]
US 10882916B2 · Kjaergaard et al. · 2021 [cited by applicant]
US 10894836B2 · Stephen et al. · 2021 [cited by applicant]
US 11130801B2 · Medof et al. · 2021 [cited by applicant]
US 11142563B2 · Igawa et al. · 2021 [cited by applicant]
US 20040132101A1 · Lazar et al. · 2004 [cited by applicant]
US 20110002931A1 · Tamburini · 2011 [cited by applicant]
US 20180256646A1 · Medof et al. · 2018 [cited by applicant]
US 20180258161A1 · Igawa et al. · 2018 [cited by applicant]
US 20180282425A1 · Guo et al. · 2018 [cited by applicant]
US 20180319877A1 · Ruike et al. · 2018 [cited by applicant]
US 20190134020A1 · Deng et al. · 2019 [cited by applicant]
US 20190225708A1 · Bosteels et al. · 2019 [cited by applicant]
US 20190248897A1 · Ng et al. · 2019 [cited by applicant]
US 20190292269A1 · Monnet · 2019 [cited by applicant]
US 20190300621A1 · Ravetch et al. · 2019 [cited by applicant]
US 20200017598A1 · Andersson et al. · 2020 [cited by applicant]
US 20200095310A1 · Regula et al. · 2020 [cited by applicant]
US 20200131253A1 · Parren et al. · 2020 [cited by applicant]
US 20200148779A1 · Yamniuk et al. · 2020 [cited by applicant]
US 20200181257A1 · Kuramochi et al. · 2020 [cited by applicant]
US 20200199241A1 · Igawa et al. · 2020 [cited by applicant]
US 20200247897A1 · Jensen et al. · 2020 [cited by applicant]
US 20200299400A1 · Lonberg et al. · 2020 [cited by applicant]
US 20200316171A1 · Pandey · 2020 [cited by applicant]
US 20200332022A1 · Labrijn et al. · 2020 [cited by applicant]
US 20200376135A1 · Boitano et al. · 2020 [cited by applicant]
US 20210070860A1 · Marasco et al. · 2021 [cited by applicant]
US 20210070875A1 · Yang et al. · 2021 [cited by applicant]
US 20210238300A1 · Kjaergaard et al. · 2021 [cited by applicant]
US 20210261648A1 · Katada et al. · 2021 [cited by applicant]
US 20210285964A1 · Mcknight et al. · 2021 [cited by applicant]
US 20220135658A1 · Neugebauer et al. · 2022 [cited by applicant]
US 20220356263A1 · Viswanathan et al. · 2022 [cited by applicant]
CN 110072887A · 2019 [cited by applicant]
EP 1587540A2 · 2005 [cited by applicant]
EP 1443961B1 · 2009 [cited by applicant]
EP 1706424B1 · 2009 [cited by applicant]
EP 1701611B1 · 2011 [cited by applicant]
EP 2679681A1 · 2014 [cited by applicant]
EP 1476469B1 · 2015 [cited by applicant]
EP 2345671B1 · 2015 [cited by applicant]
EP 2940043A1 · 2015 [cited by applicant]
EP 2994488A1 · 2016 [cited by applicant]
EP 2506871B1 · 2016 [cited by applicant]
EP 2552955B1 · 2017 [cited by applicant]
EP 2673299B1 · 2017 [cited by applicant]
EP 2371861B1 · 2017 [cited by applicant]
EP 2486141B1 · 2018 [cited by applicant]
EP 2691417B1 · 2018 [cited by applicant]
EP 2718322B1 · 2018 [cited by applicant]
EP 3004174B1 · 2019 [cited by applicant]
EP 2844289B1 · 2019 [cited by applicant]
EP 3141260B1 · 2019 [cited by applicant]
EP 3541837A1 · 2019 [cited by applicant]
EP 3576793A1 · 2019 [cited by applicant]
EP 2943507B1 · 2020 [cited by applicant]
EP 3608339A1 · 2020 [cited by applicant]
EP 3630832A1 · 2020 [cited by applicant]
EP 3630833A1 · 2020 [cited by applicant]
EP 3424953B1 · 2020 [cited by applicant]
EP 2698431B1 · 2020 [cited by applicant]
EP 3768315A1 · 2021 [cited by applicant]
EP 3411400B1 · 2021 [cited by applicant]
JP 5162587B2 · 2013 [cited by applicant]
WO 9500164A1 · 1995 [cited by applicant]
WO 2004082568A3 · 2005 [cited by applicant]
WO 2005050199A1 · 2005 [cited by applicant]
WO 2008008482A2 · 2008 [cited by applicant]
WO 2008022390A1 · 2008 [cited by applicant]
WO 2009103113A1 · 2009 [cited by applicant]
WO 2011100477A2 · 2011 [cited by applicant]
WO 2012168199A1 · 2012 [cited by applicant]
WO 2018065389A1 · 2018 [cited by applicant]
WO 2018145075A1 · 2018 [cited by applicant]
WO 2018183520A1 · 2018 [cited by applicant]
WO 2018218056A1 · 2018 [cited by applicant]
WO 2018224609A1 · 2018 [cited by applicant]
WO 2018234118A1 · 2018 [cited by applicant]
WO 2018217988A9 · 2019 [cited by applicant]
WO 2019125846A1 · 2019 [cited by applicant]
WO 2019183362A1 · 2019 [cited by applicant]
WO 2020112781A1 · 2020 [cited by applicant]
WO 2020182974A1 · 2020 [cited by applicant]
WO 2021041715A2 · 2021 [cited by applicant]
WO 2021146320A1 · 2021 [cited by applicant]
WO 2021180063A1 · 2021 [cited by applicant]
WO 2021190770A1 · 2021 [cited by applicant]
International Search Report and Written Opinion for PCT/US2021/013284 dated May 4, 2021 (13 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/012317 dated Jun. 17, 2022 (22 pages). [cited by applicant]
Akamizu, T. , et al., “Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity”, Clinical & Experimental Immunology, vol. 12… [cited by applicant]
Anliker-Ort, Marion , et al., “Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway”, Frontiers in Immunology, vol. 11, Article 599417, Dec. 2020, pp. 1-20, DOI: 10.3389/fimmu.… [cited by applicant]
Bekker, Pirow , et al., “Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Rando… [cited by applicant]
Grayson, Peter C., et al., “Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis”, Seminars in Arthritis and Rheumatism, vol. 42, No. 3, Dec. 2011, pp. 424-433, DOI: 10.1016/j.semarthrit.2011.02… [cited by applicant]
Huang, Lili , et al., “Discovery of human antibodies against the c5aR target using phage display technology”, Journal of Molecular Recognition, vol. 18, 2005, pp. 327-333, DOI: 10.1002/jmr.735 (7 pages). [cited by applicant]
Ke, Shaoying , et al., “Expression of CD88 and its effect on invasiveness of gastric carcinoma”, Chinese Journal of Surgical Oncology, vol. 8, No. 3, Jun. 20, 2016 (4 pages). [cited by applicant]
Knight, A. , et al., “Late-onset neutropenia after rituximab in ANCA-associated vasculitis”, Scandinavian Journal of Rheumatology, vol. 45, No. 5, 2016, pp. 404-407, DOI: 10.3109/03009742.2016.1138318 (5 pages). [cited by applicant]
Kussie, Paul H., et al., “A single engineered amino acid substitution changes antibody fine specificity”, The Journal of Immunology, vol. 152, No. 1, Jan. 1994, pp. 146-152, DOI: 10.4049/jimmunol.152.1.146 (8 pages). [cited by applicant]
La-Crette, Jonathan , et al., “Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis”, Clinical Rheumatology, vol. 37, 2018, pp. 1085-1090, DOI: 10… [cited by applicant]
Mehta, Guarav , et al., “A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA”, Journal of immunology (Baltimore, Md. : 1950), vol. 194, No.… [cited by applicant]
Melis, Joost P.M., et al., “Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics”, Molecular Immunology, vol. 67, 2015, pp. 117-130, DOI: 10.1016/j.molimm.2015.01.028 (14 … [cited by applicant]
Ohlsson, Sophie , et al., “Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation”, PLOS One, vol. 14, No. 6,… [cited by applicant]
Rudikoff , et al., “Single amino acid substitution altering antigen-binding specificity”, Proceedings of the National Academy of Sciences USA, Immunology, vol. 79, Mar. 1982, pp. 1979-1983 (5 pages). [cited by applicant]